Autopsy report · NCT03127592

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

“recruitment difficulty”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 6 months before it started.
• Ran for about 1 year 10 months before it stopped.
• 140 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Apsen Farmaceutica S.A.

Sponsor type

Industry

Conditions

Pain, Acute

Interventions

Fixed Dose Combination; Etodolac; Cyclobenzaprine

Participants

140

Sites

1

Countries

Brazil

Trials that died the same way

• Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain
  “difficulty of recruitment” (97% match in meaning)
• Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis
  “Difficulty in recruitment” (97% match in meaning)
• Neuropsychological Factors Associated With Vulnerability to Suicidal Behavior in Depressed Elderly Patients
  “recruitment difficulties” (95% match in meaning)
• Robotic Decompression of the Pudendal Nerve in Pudendal Neuralgia
  “recruitments difficulties” (94% match in meaning)
• ACTHAR Therapy for Central Nervous System Sarcoidosis
  “Difficulty with recruitment” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.